For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
- Abe Tells Key Govt Panel to Compile FY2016 Economic, Fiscal Blueprint by May-End
May 12, 2016
- National Cancer Center to Strengthen Systems for Genome-Based Personalized Medicine and Rare Cancers: Pres. Nakagama
May 12, 2016
- MHLW Orders Teijin Pharma to Review Documents Submitted for Reexamination of 6 Products Including Bonalon
May 12, 2016
- Pharmacists Can Make Big Contribution to Health Finances by Reducing Drug Waste: MHLW Study Group Chief
May 10, 2016
- 18 of 24 Drug Firms in Kumamoto Have No Production Problem after Quakes: MHLW Update
May 10, 2016
- Bisphosphonates under Review for Risk of Osteonecrosis of External Auditory Canal
May 9, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
- Chuikyo Member Prods MHLW to Present Data on Savings through Generic Use
April 28, 2016
- Govt Achieves 8 Numerical Targets for FY2015 Plan to Promote R&D in Healthcare Field
April 28, 2016
- Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018
April 27, 2016
- Japan BCG Faces Business Improvement Order over Manufacturing Methods
April 27, 2016
- MHLW Panel Supports Ono’s Cancer Drug Carfilzomib
April 26, 2016
- 13 New Countries Join Japan-EU Mutual Acceptance Scheme for GMP Data
April 26, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Sovaldi, Harvoni, Other Hep C Drugs
April 26, 2016
- PMDA Now Has 560 Full-Time Employees in Review Division
April 25, 2016
- Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
- Panel Eyes FY2017 Discussion Deadline for Prescribing Rules for Lifestyle Disease Drugs
April 22, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…